Yale School of Medicine (YSM) researchers have tested a new and potentially more sensitive neuroimaging tool for diagnosing ...
FDA acceptance positions 18F-FET as a potential first-in-class US-approved amino acid PET agent for glioma characterization, addressing a major posttreatment imaging specificity gap.
Please provide your email address to receive an email when new articles are posted on . A 63-year-old male was referred to the endocrine clinic for the management of advanced thyroid cancer. Nine ...
Prognostic pathological and clinical factors associated with overall survival in metastatic melanoma undergoing anti PD-1 treatment. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting ...
Background Cardiac sarcoidosis (CS) creates complex treatment challenges, especially for patients who fail to respond to immunosuppressive drugs, including second-line tumour necrosis factor ...
Gastric cancers accounted for 11,180 deaths in the U.S. alone in 2021, and almost two-thirds are diagnosed at an advanced stage. A recent study evaluated the efficacy of 18F-FDG PET/CT to determine ...
Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results